Genetic study links vitamin B1 metabolism to gut motility and IBS risk

	Gastroenterology
	The latest gastroenterology‎ news from News Medical

	Genetic study links vitamin B1 metabolism to gut motility and IBS risk Research links thiamine metabolism to gut motility, identifying genetic markers that could lead to new therapies for IBS and related digestive disorders.

	PTPN2 gene protects the gut from harmful bacteria driving inflammatory bowel disease Two recent studies from the University of California, Riverside, published in the same issue of Gut Microbes highlight the role of a gene called PTPN2 in protecting the gut from harmful bacteria linked to inflammatory bowel disease (IBD).

			Can edible cactus improve blood sugar and cholesterol? A scientific review Edible cacti, especially Opuntia cladodes, show consistent short-term benefits for postprandial blood glucose and modest improvements in lipid biomarkers, largely driven by soluble fiber and bioactive compounds. Human evidence for gut microbiota modulation and long-term cardiometabolic outcomes remains preliminary, supporting cactus as a complementary dietary strategy rather than a therapeutic intervention.

			Discovery explains why people with IBD have higher risk of colorectal cancer A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone marrow—may help explain why people with inflammatory bowel disease (IBD) have a higher risk of colorectal cancer, according to a preclinical study by Weill Cornell Medicine investigators.

	Expert guidance on fecal microbiota transplantation in liver disease The gut microbiota plays a crucial role in maintaining host health and liver function. Fecal microbiota transplantation (FMT), an emerging therapeutic modality, has demonstrated promising potential in the treatment of chronic liver diseases.

	Unveiling ADC cellular internalization with pH-sensitive dye detection Learn how pH-sensitive dye detection supports reliable ADC internalization assays and insight into cellular uptake mechanisms.

	Long-term proton pump inhibitor use not linked to stomach cancer The long term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased risk of developing gastric (stomach) cancer, finds a study of Nordic health data published by The BMJ today.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2026